drugset
Drugs / MINOZAC FREE BASE
last change Jul 2025 re-read 3 minutes ago

MINOZAC FREE BASE

also known as MW151 · MW01-2-151SRM

Small molecule

Developed for
cognitive disorder
Investigated by
Duke Clinical Research Institute · ImmunoChem Therapeutics, LLC · Linda Van Eldik · National Cancer Institute (NCI) · National Institute on Aging (NIA) · Northwestern Medicine

Trials 2

today NCT05417282 · Ph 1 NCT04120233 · Ph 1
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05417282 Jul 2022 → Jul 2025 cognitive disorder ImmunoChem Therapeutics, LLC Completed No outcome recorded
Phase 1 NCT04120233 Oct 2019 → Sep 2021 poisoning Linda Van Eldik Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as MINOZAC FREE BASE ChEMBL registry synonym — accepted as the source's own label CHEMBL232211 ↗
Known as MW01-2-151SRM “MW01-2-151SRM (=MW151), a small molecule, is being developed for the treatment of cognitive disorders.” NCT04120233 ↗
Known as MW151 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05417282 ↗
1

NCT04120233 ↗
Modality Small molecule “MW01-2-151SRM (=MW151), a small molecule, is being developed for the treatment of cognitive disorders.” NCT04120233 ↗
Route Oral “10 mg MW151, 1 x 10mg capsule administered orally” NCT04120233 ↗